NEW 1 (1 (HETERO) ARYL-1-PERHYDROXYALKYLMETHYL) - PIPERAZINVERBINDUNGEN, PROCEDURE FOR YOUR PRODUCTION AND THESE CONNECTIONS CONTAINING DRUGS

NOVEL UREA DERIVATIVES

Compounds of Formula I wherein R1 is hydrogen or lower alkyl, R2 is hydrogen or halogen and R3 is hydrogen or lower alkoxy, and their pharmacologically acceptable acid addition salts and pharmaceutical compositions containing these compounds and also processes for the preparation of these compounds.

7-PHENYL-1,4-DIAZEPANE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Neurokinin-antagonistic compounds corresponding to formula I: in which R1 is hydrogen or lower alkyl, R2 is hydrogen, lower alkyl, lower alkoxy, halogen or trifluoromethyl, and R3 is hydrogen, lower alkyl, lower alkoxy, halogen or trifluoromethyl, or R2 and R3 together are alkylenedioxy with 1 to 2 carbon atoms, bonded to adjacent carbon atoms of the phenyl ring, R4 is hydrogen, lower alkyl, lower alkoxy, halogen or trifluoromethyl, and R5 is hydrogen, lower alkyl, lower alkoxy, halogen or trifluoromethyl, or R4 and R5 together are alkylenedioxy with 1 to 2 carbon atoms, bonded to adjacent carbon atoms of the phenyl ring, R6 is lower alkyl, halogen or trifluoromethyl, R7 is lower alkyl, halogen or trifluoromethyl, A is a -(CH2) n- group in which n represents an integer from 1 to 3, or an -NH-(CH2) m - group in which m represents an integer from 2 to 3, and B is an alkylene chain with 1 to 3 carbon atoms optionally substituted by lower alkyl, and physiologically acceptable salts thereof ...

2,9-DIOXATRICYCLO (4,3,1,03,7) - DECANE AND PROCEDURE FOR THEIR PRODUCTION.

Process for preparing novel 3-azidomethyl-2,0-dioxatricyclo[4.3.1.0<3,7>]decanes

Novel compounds of the formula IA in which R1 denotes hydrogen, R2 denotes hydroxyl and R3 denotes alkoxy or aralkoxy, are obtained from a compound of the formula II in which Hal denotes chlorine, bromine or iodine, R2 denotes acetoxy and R3 denotes alkoxy or aralkoxy. The hydrogenation of the 10, 11 double bond, the conversion of the 3-halomethyl group and the hydrolysis of the 4 beta -acyloxy group yield the compounds of the formula IA, in which R1 denotes H and R2 denotes OH. The corresponding 4 alpha compound is obtained from the 4 beta compound by oxidation to give the 4-one compound, and selective reduction thereof. The 4 alpha -OH group or 4 beta -OH group can be acylated or carbamoylated. The novel compounds exhibit analgesic, antipyretic and antiinflammatory effects.

NEW COMPOUNDS OF 1 [1 (HETERO) ARIL-1-PERHIDROXIALQUILMETIL] - PIPERAZINA, PROCEDURES FOR ITS PREPARATION, AND MEDECINES THAT CONTAIN THESE COMPOUNDS

Compuestos de 1-[1-(hetero)aril-1-perhidroxialquilmetil]-piperazina con actividad antagonista de receptores de taquicininas, de fórmula general (1), en la cual A significa naftilo, fenilo eventualmente sustituido con hidroxi, heteroarilo mono- o bicíclico, o alquenilo C3-6 eventualmente sustituido con fenilo; Z significa un subgrupo de fórmula general -(CHOR1)k-(CHOR2)l-(CHOR3)m-(CHOR4)n-CH2OR5, en la cual R1 significa hidrógeno o alcanoilo inferior, o bien puede formar, conjuntamente con otro sustituyente seleccionado del grupo compuesto por R2, R3, R4 y R5, un anillo de 5 ó 6 miembros, puenteado a través de carbonilo, tiocarbonilo, o a través de metileno eventualmente sustituido con alquilo inferior o con alquileno C4-5; R2 significa hidrógeno o alcanoilo inferior, o bien puede formar, conjuntamente con otro sustituyente seleccionado del grupo compuesto por R1, R3, R4 y R5, un anillo de 5 ó 6 miembros, puenteado a través de carbonilo, tiocarbonilo o a través de metileno eventualmente ...

PHENYLALKYLAMINOALKYL CONNECTIONS AS WELL AS PROCEDURES FOR YOUR PRODUCTION AND THESE CONNECTIONS CONTAINING DRUGS

PHARMACEUTICALLY ACTIVE PHENYLALKYLAMINO-ALKYL COMPOUNDS

7-phenyl-1, 4-diazepane derivatives, processes for the preparation thereof and medicaments containing these compounds

2,6-DIOXA-BICYCLO-(2,2,2)-OCTAN-7-YL-ACETALDEHYDES

... 2,6-dioxa-bicyclo-¢2,2,2!-octane-7-yl-acetaldehydes of the general Formula I, < IMG > I wherein R1 is a benzyl or lower alkyl group, and A and B either are each hydrogen or together represent a single bond between their respective carbons, and a method for producing such compounds. The compounds are valuable intermediates in the synthesis of pharmacologically active substances having, for example, cardiovascular effects, ...

Hydronopol substituted benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors

The invention relates to a group of hydronopol substituted benzimidazolone and quinazolinone derivatives which are agonists on human ORL1 (nociceptin) receptors. The invention also relates to the preparation of these compounds, to pharmaceutical compositions containing a pharmacologically active amount of at least one of these novel benzimidazolone and quinazolinone derivatives as an active ingredient, as well as to the use of these pharmaceutical compositions for the treatment of disorders in which ORL1 receptors are involved. The invention relates to compounds of the general formula (1), wherein the symbols have the meanings as given in the description.

IMIDAZOL-1-YL-VERBINDUNG CONTAINING DRUGS

PROCEDURE FOR FINDING CONNECTIONS, WHICH FOR THE TREATMENT AND/OR PROPHYLAXIS ARE SUITABLE OF OBESITAS

Pharmaceutically active phenylalkylamino-alkyl compounds

Therapeutic use of myelin-associated glycoprotein (mag)

METHOD OF TREATING COLON DISTURBANCES WITH PHARMACEUTICAL COMPOSITIONS CONTAINING IMIDAZOL-1-YL COMPOUNDS

Use of imidazol-1-yl compounds of the general formula I wherein R1 denotes lower alkyl or hydrogen; m represents 2 or 3, and n represents 2 or 3; or a physiologically acceptable acid addition salt thereof for treating functional disturbances of the lower intestinal tract in larger mammals and humans associated with increased pain sensitivity and/or anomalies in stool passage in the colon region.

CERULOPLASMIN ANALOGS AND METHODS OF USE

The present invention relates to ceruloplasmin analogs having a unique glycosylp hosphatidyl-inolsitol (GPI) moiety that anchors this form of ceruloplasmin to the cell surface of astr ocytes in the mammalian central nervous system. The invention also relates to cDNA sequenc es encoding said ceruloplasmin analogs and recombinant plasmids and host cells for analog ex pression. The invention also provides monoclonal antibodies to the protein, the nucleic acid s equences and their use in diagnosis, research and therapy. The invention further relates to u se of said ceruloplasmin analogs to treat conditions where toxic levels of ferrous iron pla y a role, such as Parkinsons' disease, Alzheimers' disease, amyotrophic lateral sclerosis, acerulo plasminemia and Hallervorden-Spatz disease.

GPI-CERULOPLASMIN, ANALOGS THEREOF, AND METHODS OF USE

The present invention relates to ceruloplasmin having a unique glycosylphosphat idyl-inositol moiety (GPI-ceruloplasmin) and analogs thereof that anchors this form of cerulop lasmin to the cell surface of astrocytes in the mammalian central nervous system (CNS) and to leptomeningeal cells that cover the CNS. The invention also relates to cDNA sequences encoding said GPI-ceruloplasmin, and analogs thereof, and recombinant plasmids and host cells for expression. The invention also provides monoclonal antibodies to the protein, the nucleic ac id sequences and their use in diagnosis, research and therapy. The invention further relates to u se of said GPI-ceruloplasmin, and analogs thereof, to treat conditions where toxic levels of ferrous iron play a role, such as Parkinsons' disease, Alzheimers' disease, amyotrophic lateral scle rosis, aceruloplasminemia and Hallervorden-Spatz disease.

ALKYLAMINOALKYLAMIN AND - ETHER CONNECTIONS AS WELL AS PROCEDURES AND INTERMEDIATE PRODUCTS TO YOUR PRODUCTION AND THESE CONNECTIONS CONTAINING DRUGS

7-PHENYL-1,4-DIAZEPANDERIVATE AS NEUROKININREZEPTORANTAGONISTEN

INDOLMETHYL n, N' BISACYLPIPERAZINE AS NEUROKININREZEPTORANTAGONISTEN

2,9-DIOXATRICYCLO-(4,3,1,0,3,7)DECANES

Novel urea derivatives

ALKYLAMINOALKYLAMINE AND ETHER COMPOUNDS, PROCESSES AND INTERMEDIATES FOR THEIR PREPARATION, AND MEDICAMENTS CONTAINING THEM

Pharmacologically active compounds corresponding to the formula I in which n represents 2-5, m represents 2-6, R1 denotes hydrogen or lower alkyl, R2 represents an OR4 group in which R4 denotes lower alkyl or a phenyl or phenyl-lower alkyl group which is optionally substituted in the phenyl ring, or R2 represents a group in which R5 and R6 independently of one another each denote hydrogen, lower alkyl or a phenyl or phenyllower alkyl group which is optionally substituted in the phenyl ring, or R5 and R6, together with the nitrogen atom to which they are bonded, represent a saturated 5- or 6-membered heterocycle, R3 represents a saturated monocyclic or bicyclic hydrocarbon group which is derived from terpenes and has 10 or 11 carbon atoms, and Z represents oxygen or, if R3 is a dihydronopyl group, Z may also represent sulfur, and salts thereof.

Method for locating compounds which are suitable for the treatment and/or prophylaxis of obesity

Gpi-ceruloplasmin, analogs thereof, and methods of use

Novel urea derivatives

Nevron growth inhibitory molecules or derivatives thereof used to immunize mammals thereby promoting axon regeneration

Hydronopol substituted benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors

The invention relates to a group of hydronopol substituted benzimidazolone and quinazolinone derivatives which are agonists on human ORL1 (nociceptin) receptors. The invention also relates to the preparation of these compounds, to pharmaceutical compositions containing a pharmacologically active amount of at least one of these novel benzimidazolone and quinazolinone derivatives as an active ingredient, as well as to the use of these pharmaceutical compositions for the treatment of disorders in which ORL1 receptors are involved. The invention relates to compounds of the general formula (1) wherein the symbols have the meanings as given in the description.

Imidazol-1-yl-Verbindung enthaltende Arzneimittel

Alkylaminoalkylamines and ether compounds and process and intermediates for their preparation and medicaments containing these compounds

LIPIP COMPOSITIONS

NEURON AND NEURAL TUMOUR GROWTH REGULATORY SYSTEM, ANTIBODIES THERETO AND USES THEREOF

The present invention relates to a neuron and neural tumor growth regulatory sys tem, based on the novel protein, arretin and its isoforms and fragments thereof, its receptor, antibodies directed against the components of this system and diagnostic, therapeutic, and research uses for each of these aspects. This protein has an apparent molecular weight of approximately 70 kDa. Embodiments of the invention comprise the amino acid sequence and probes designe d therefrom for nucleic acid sequences encoding arretin. Alternatively, tagged arretin prote in for use as a reporter to detect receptors of arretin, which are then sequenced and used to ob tain probes for the nucleic acid sequences encoding arretin receptors are included. The present inve ntion further relates to arretin receptors and fragments thereof as well as the nucleic acid s equences coding for such arretin receptors and fragments, and their therapeutic and diagnostic uses. Substances which function as either agonists or antagonists ...

Treatment of neural diseases or conditions

Compounds, methods, uses, compositions, kits and packages for the prevention and/or treatment of neural injury or a neurodegenerative disease, based on the use of a retinoic acid derivative, such as fenretinide, and/or analogs, derivatives, prodrugs, precursors thereof, and/or salts thereof, are described.

2,9-DIOXA TRICYCLO [4,3,1,0.SUP.3.SUP.,.SUP.7] DECANE COMPOUNDS AND PROCESS OF MAKING SAME

Novel and highly effective sleep inducing 3.beta.-hydroxy methyl-4.alpha.- hydroxy-8.beta.-alkoxy-2,9-dioxa tricyclo ¢4,3,1,03,7! decane compounds of the following Formula: in which R1 indicates an alkoxy group and preferably a lower alkoxy group, such as the methoxy group, the ethoxy group, or the nbutoxy group, while R2 indicates the 10-methylene group or the 10.alpha.-methyl group, are produced from didrovaltratum, i.e., 1-isovaleroxy-4-isovaleroxy methyl-7-acetoxy-spiro-oxirano-1,9-dihydrocyclo-patenta(c)pyrane or from extracts of plants of the genus Valerianaceae which contain about 70% of didrovaltratum. The novel compounds have a surprisingly low toxicity.

Neue 1- 1-(Hetero)aryl-1-perhydroxyalkylmethyl -Piperazinverbindungen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel

Es werden neue, Tachykininrezeptor-antagonistisch wirksame 1-[1-(Hetero)aryl-1-perhydroxyalkylmethyl]-Piperazinverbindungen der allgemeinen Formel I, DOLLAR F1 worin R·6·, R·7·, A und Z die in der Beschreibung angegebenen Bedeutungen besitzen, sowie diese Verbindungen enthaltende Arzneimittel beschrieben. Ferner werden Verfahren zur Herstellung der neuen Verbindungen und Zwischenprodukte dieses Verfahrens beschrieben.

VERFAHREN ZUR HERSTELLUNG VON 2,9-DIOXATRICYCLO ECKIGE KLAMMER AUF 4,3,1,0 HOCH 3,7 ECKIGE KLAMMER ZU DECANEN

Method for locating compounds which are suitable for the treatment and/or prophylaxis of obesity

Hydronopol derivatives as agonists on human ORL1 receptors

Bicyclo`3.1.1 heptane substituted benzimidazolone and quinazolinone derivatives as agonisits on human ORL1 receptors

2,9-DIOXATRICYCLO(4,3,1,03,7)DECANE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF

... 4-amino-3-methyl-2,9-dioxatricyclo¢4,3,1,03,7!decane derivatives are disclosed which exhibit analgesic properties, and which have the formula (I) (I) wherein -one of R1 and R2 represents hydrogen and the other represents an amino group which is substituted by an arylalkyl group or an arylalkenyl group, -one of R3 and R4 represents hydrogen and the other represents alkoxy, and -y and y' each represent hydrogen or jointly form a bond, and pharmaceutically acceptable acid addition salts thereof, as well as pharmaceutical formulations thereof.

TREATMENT OF NEURAL DISEASES OR CONDITIONS

Compounds, methods, uses, compositions, kits and packages for the prevention and/or treatment of neural injury or a neurodegenerative disease, based on the use of a retinoic acid derivative, such as fenretinide, and/or analogs, derivatives, prodrugs, precursors thereof, and/or salts thereof, are described.

FABRIC SPREADING AND LAYING DEVICE

PHENYLALKYLAMINOALKYL COMPOUNDS, METHODS FOR PREPARING THEM, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Pharmacologically active compounds corresponding to the general formula I: wherein m represents 1-4, n represents 2-5, R1 is hydrogen or lower alkyl, R2 is hydrogen, lower alkyl, lower alkoxy, halogen or trifluoromethyl, and R3 is hydrogen, lower alkyl, lower alkoxy or halogen, or R2 and R3 are linked to adjacent carbon atoms and together form an alkylenedioxy group with 1-2 carbon atoms, R4 represents a saturated monocyclic or bicyclic hydrocarbon radical derived from terpenes and having 10 or 11 hydrocarbon atoms, and Z represents oxygen, an N-R5 group, wherein R5 is lower alkyl, or if R4 is a dihydronopyl radical, Z may also be sulfur, and their acid addition salts.

NOVEL UREA DERIVATIVES

Compounds of Formula I (see formula I) wherein R1 is hydrogen or lower alkyl, R2 is hydrogen or halogen and R3 is hydrogen or lower alkoxy, and their pharmacologically acceptable acid addition salts and pharmaceutical compositions containing these compounds and also processes for the preparation of these compounds.

Urea derivatives

Bicyclo[3.1.1]heptane substituted benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors

Novel 1-[-(hetero)aryl-1-perhydroxyalkylmethyl])-piperazine compounds, process for their preparation and medicaments containing these compounds

3-AZIDOMETHYL-2,9-DIOXATRICYCLO(4,3,1,03,7)DECANES

NEURON AND NEURAL TUMOR GROWTH REGULATORY SYSTEM, ANTIBODIES THERETO AND USES THEREOF

Le précis n'est pas disponible en Not Yet Available ce moment ...

Hydronopol derivatives as agonists on human orl1 receptors

The invention relates to a group of hydronopol derivatives which are agonists on human ORL1 (nociceptin) receptors. The invention also relates to the preparation of these compounds, to pharmaceutical compositions containing a pharmacologically active amount of at least one of these novel hydronopol derivatives as an active ingredient, as well as to the use of these pharmaceutical compositions for the treatment of disorders in which ORL1 receptors are involved. The invention relates to compounds of the general formula (1), , wherein the symbols have the meanings as given in the description.

Neuron and neural tumour growth regulatory system, antibodies thereto and uses thereof

LIPIP COMPOSITIONS

USE OF INHIBITORS OF PHOSPHOLIPASE A2 FOR THE TREATMENT, PREVENTION OR DIAGNOSIS OF NEURAL INFLAMMATORY OR DEMYELINATING DISEASE

2,9-DIOXATRICYCLO(4,3,1,03,7)DECANES

METHOD FOR LOCATING COMPOUNDS WHICH ARE SUITABLE FOR THE TREATMENT AND/OR PROPHYLAXIS OF OBESITY

The invention relates to a method for locating compounds which are suitable for the treatment and/or prophylaxis of obesity, whereby the ability of the examined compounds to inhibit de novo lipogenase in mammals and/or humans is determined. Also disclosed is the use of compounds which are capable of inhibiting de novo lipogenase in mammals in the production of medicaments for the treatment and/or phophylaxis of obesity. © KIPO & WIPO 2007 ...

SEMICONDUCTOR LASER

PROBLEM TO BE SOLVED: To provide a semiconductor laser which can detect outgoing power suitably in a semiconductor laser which offers a fixed optical path by using a grating and a mirror. SOLUTION: The grating 3 performs light receiving of laser light from a laser diode 1 through a lens 2, emits primary diffracted light to the laser diode 1 and emits 0th light to the mirror 4. The 0th light is reflected with the mirror 4 and made to enter a beam splitter 5. Spectrum of the incident light is performed into transmitting light and reflected light. The reflected light is made to enter a detector 6, and outgoing power is detected. The grating 3 and the mirror 4 are rotated by using an axis of rotation 7 as a center, and wavelength of laser light emitted from the laser diode 1 is adjusted. Optical path of the transmitting light and the reflected light offered from the beam splitter 5 is not changed by the above rotation. COPYRIGHT: (C)2005,JPO&NCIPI ...

Neue 1-(1-(Hetero)aryl-1-perhydroxyalkylmethyl)-Piperazinverbindungen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel

Method for locating compounds which are suitable for the treatment and/or prophylaxis of obesity

Alkylaminoalkylamin- und -äther- Verbindungen sowie Verfahren und Zwischenprodukte zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel

ALKYLAMINOALKYLAMINES AND ETHER COMPOUNDS AND PROCESS AND INTERMEDIATES FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING THESE COMPOUNDS

Method of treating or inhibiting obesity

A method for the discovery of compounds suitable for the treatment and/or prophylaxis of obesity, in which the ability of the test compounds to inhibit de novo lipogenesis in mammals and/or man is determined. The use of compounds which are capable of inhibiting de novo lipogenesis in mammals, and which are substantially free of effects directed towards the CNS, for the preparation of pharmaceutical compositions for the treatment and/or prophylaxis of obesity, as well as for the treatment and/or inhibition of obesity, are also described.

VERFAHREN ZUR HERSTELLUNG VON 2,9-DIOXATRICYCLO ECKIGE KLAMMER AUF 4,3,1,0 HOCH 3,HOCH 7 ECKIGE KLAMMER ZU DECANEN

1-[1-(hetero)aryl-1-perhydroxyalkylmethyl]-piperazine compounds, process for their preparation and pharmaceutical compositions containing them

Novel 1-[1-(hetero)aryl-1-perhydroxyalkylmethyl]-piperazine compounds which are antagonistic to tachykinin receptors, of the general formula I,wherein R<6>, R<7>, A and Z have the meanings given in the description, and pharmaceutical compositions containing these compounds, as well as a process for the preparation of such compounds and intermediate products of this process.

Indolmethyl-N,N'-bisacylpiperazine als Neurokininrezeptorantagonisten

7-phenyl-1,4-stable derivative, its preparing method and medicine containing said compound

7-Fenil-1,4-Diazepan türevleri ve bunları içeren ilaçlar.

7-Phenyl-1,4-diazepanderivate als Neurokininrezeptorantagonisten

DERIVATIVES AS AGONISTS OF HUMAN ORL -1 RECEPTOR.

Se refiere a un grupo de derivados de hidronopol que son agonistas de receptores ORL1 humanos (nociceptina). También se refiere a la preparación de estos compuestos, a composiciones farmacéuticas que contienen como ingrediente activo una cantidad farmacológicamente activa de al menos uno de estos nuevos derivados de hidronopol, como así también al uso de estas composiciones farmacéuticas para el tratamiento de trastornos en los cuales están implicados receptores ORL1. Se refiere a compuestos de fórmula general 1 donde los símbolos tienen los significados dados en la memoria descriptiva.

BICYCLO'3.1.1!HEPTANE SUBSTITUTED BENZIMIDAZOLONE AND QUINAZOLINONE DERIVATIVES AS AGONISTS ON HUMAN ORL1 RECEPTORS

The invention relates to a group of hydronopol substituted benzimidazolone and quinazolinone derivatives which are agonists on human ORL1 (nociceptin) receptors. The invention also relates to the preparation of these compounds, to pharmaceutical compositions containing a pharmacologically active amount of at least one of these novel benzimidazolone and quinazolinone derivatives as an active ingredient, as well as to the use of these pharmaceutical compositions for the treatment of disorders in which ORL1 receptors are involved. The invention relates to compounds of the general formula (1) wherein the symbols have the meanings as given in the description. © KIPO & WIPO 2007 ...

TREATMENT OF NEURAL DISEASES OR CONDITIONS

Compounds, methods, uses, compositions, kits and packages for the prevention and/or treatment of neural injury or a neurodegenerative disease, based on the use of a retinoic acid derivative, such as fenretinide, and/or analogs, derivatives, prodrugs, precursors thereof, and/or salts thereof, are described. 1. A method for treating a neurodegenerative disease in a subject , said method comprising administering to said subject an effective amount of (i) fenretinide; (ii) a pharmaceutically-acceptable salt of fenretinide; or (iii) any combination of (i) and (ii).2. The method according to claim 1 , comprising administering to said subject an effective amount of fenretinide.3. The method according to claim 1 , wherein said neurodegenerative disease is Amyotrophic Lateral Sclerosis (ALS).4. The method according to claim 1 , wherein said method further comprises treatment or inhibition of a condition selected from (a) neural inflammation; (b) loss of neural cell or tissue; (c) increased neural arachidonic acid (AA) levels; (d) decreased neural docosahexaenoic acid (DHA) levels; (e) neural oxidative stress; and (f) any combination of (a) to (e).5. The method according to claim 3 , wherein said AA levels are phospholipid-bound AA levels.6. The method according to claim 3 , wherein said DHA levels are phospholipid-bound DHA levels.7. The method according to claim 1 , wherein said subject is a mammal.8. The method according to claim 7 , wherein said mammal is a human.9. The method according to claim 2 , wherein said method further comprises treatment or inhibition of a condition selected from (a) neural inflammation; (b) loss of neural cell or tissue; (c) increased neural arachidonic acid (AA) levels; (d) decreased neural docosahexaenoic acid (DHA) levels; (e) neural oxidative stress; and (f) any combination of (a) to (e).10. The method according to claim 2 , wherein said subject is a mammal.11. The method according to claim 10 , wherein said mammal is a human.12. The method ...

HYDRONOPOL DERIVATIVES AS AGONISTS ON HUMAN ORL1 RECEPTORS

The invention relates to a group of hydronopol derivatives which are agonists on human ORL1 (nociceptin) receptors. The invention also relates to the preparation of these compounds, to pharmaceutical compositions containing a pharmacologically active amount of at least one of these novel hydronopol derivatives as an active ingredient, as well as to the use of these pharmaceutical compositions for the treatment of disorders in which ORL1 receptors are involved. The invention relates to compounds of the general formula (1) wherein the symbols have the meanings as given in the description. © KIPO & WIPO 2007 ...

Neue Imidazol-1-yl-Verbindungen enthaltende Arzneimittel

Selection and use of lipogenesis inhibitors for the treatment and prevention of obesity

The invention relates to a method for locating compounds which are suitable for the treatment and/or prophylaxis of obesity, whereby the ability of the examined compounds to inhibit de novo lipogenase in mammals and/or humans is determined. Also disclosed is the use of compounds which are capable of inhibiting de novo lipogenase in mammals in the production of medicaments for the treatment and/or phophylaxis of obesity.

MEDICINAL COMPOSITION FOR TREATING FUNCTION DISORDER OF LOWER COLON ASSOCIATED WITH HYPERALGESIA IN COLIC REGION AND DEJECTION DISORDER

PURPOSE: To provide a new medicinal compsn. for treatment of the gastrointestinal function disorder of the lower colic region. CONSTITUTION: This medicinal compsn. contains the imidazol-1-yl compd. of the formula (R1 is a lower alkyl, H; m, n are 2, 3) and its physiologically permissible acid addition salts; for example, 5,6,9,10-tetrahydro-10-[(2-methyl-1H- imidazol-1-yl)-methyl]-4H-pyrido[3,2,1-jk]carbazol-11(8H) one and treats the hyperalgesia in the colic region of the large-sized mammals and human and/or the function disorder of the lower colon associated with the dejection disorder. The compd. lowers the hyperalgesia of the internal organs, thereby making it possible to prohibit the suppression of the colic motion based on the irritable reaction to the colic extension. The compd. additionally has the action to delay the dejection through the colon, thereby making it possible to make the abnormally accelerated colic passage to normal. COPYRIGHT: (C)1994,JPO ...

VERFAHREN ZUM AUFFINDEN VON VERBINDUNGEN, WELCHE ZUR BEHANDLUNG UND/ODER PROPHYLAXE VON OBESITAS GEEIGNET SIND

NOVEL 1-[1-(HETERO)ARYL-1-PERHYDROXYALKYLMETHYL]-PIPERAZINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING THESE COMPOUNDS

PURPOSE: Provided are novel 1-[1-(hetero)aryl-1-perhydroxyalkylmethyl]-piperazine compounds which are tachykinin receptor antagonists and to medicaments containing these compounds. Furthermore, provided is a process for preparing the novel piperazine compounds and intermediate products of this process. CONSTITUTION: A compound is characterized by corresponding to the formula I, wherein A is naphthyl, phenyl optionally substituted by hydroxy, mono- or bicyclic heteroaryl or C3-6-alkenyl optionally substituted by phenyl, Z is a subgroup corresponding to the formula, R^6 is halogen or hydrogen, and R^7 is halogen or hydrogen. © KIPO 2003 ...

PROCEDURE TO FIND COMPOUND THAT THE TREATMENT AND/OR THE PROPHYLAXIS OF THE OBESITY AND USE OF THESE COMPOUNDS ARE ADAPTED FOR

Un procedimiento para encontrar compuestos que son adecuados para el tratamiento y/o la profilaxis de la obesidad, determinando la capacidad de los compuestos a investigar de inhibir la lipogénesis de nuevo en mamíferos y/o seres humanos. Utilizacion de compuestos que poseen la capacidad de inhibir la lipogénesis de nuevo en mamíferos y que están esencialmente exentos de efectos dirigidos al SNC, para la preparacion de medicamentos para el tratamiento y/o profilaxis de la obesidad.

Hydronopol derivatives as agonists on human ORL1 receptors

The invention relates to a group of hydronopol derivatives which are agonists on human ORL1 (nociceptin) receptors. The invention also relates to the preparation of these compounds, to pharmaceutical compositions containing a pharmacologically active amount of at least one of these novel hydronopol derivatives as an active ingredient, as well as to the use of these pharmaceutical compositions for the treatment of disorders in which ORL1 receptors are involved. The invention relates to compounds of the general formula (1) wherein the symbols have the meanings as given in the description.

Amides as inhibitors of human secreted phospholipase A2

Methods and compounds useful for inhibiting a phoshpolipase A2 are provided, the methods comprising contacting the phoshpolipase A2 with a compound having the structure A, or pharmaceutically acceptable salts thereof: wherein R1 is H, F, NH2, or COOH; R2 is, H, linear saturated or unsaturated alkyl, alkenyl, or alkynyl; each of R3 and R4 is independently H, linear saturated or unsaturated alkyl, alkenyl, alkynyl, phenyl, or substituted phenyl; R5 is H, (C1-C6) alkyl such as methyl or ethyl; X is aryl or substituted aryl, such as phenyl or a substituted phenyl; and Y is O or S.

Used of inhibitors of phospholipase a2 for the treatment, prevention or diagnosis of neural inflammatory or demyelinating disease

The present invention provides methods of preventing and treating neural inflammatory or demyelinating disease, such as multiple sclerosis, via an inhibition of the activity or expression of phospholipase A₂. The invention further relates to methods of identifying phospholipase A₂ inhibitors and their use thereof for the prevention and/or treatment of neural inflammatory or demyelinating disease. An observed increase in the amount of phospholipase A₂ in neural lesions in the EAE animal model system indicates that elevated phospholipase A₂ activity or levels correlate with neural inflammatory or demyelinating disease. Therefore, in a further aspect the invention provides methods for the diagnosis and prognostication of neural inflammatory or demyelinating disease, such as multiple sclerosis.

Phospholipase A2 inhibitors and their use in treating neurological injury and disease

Phospholipase A2 (PLA2) forms are expressed in spinal cord whose inhibition induces a potent antihyperalgesia. PLA2 inhibitor compounds are provided that include a common motif consisting of a 2-oxoamide with a hydrocarbon tail and a four carbon tether. The compounds block Group IVA calcium dependent PLA2 (cPLA2) and/or Group VIA calcium independent PLA2 (iPLA2) and/or Group V secreted PLA2 (sPLA2). Pharmaceutical compositions of compounds having cPLA2 inhibitory activity (but not iPLA2 or sPLA2 inhibitory activity) are useful in treating multiple sclerosis, while compositions of compounds having sPLA2 inhibitory activity (as well as iPLA2 and CPLA2 activity) are useful in treating spinal cord injuries (with related functional recovery).

Treatment of neural diseases or conditions

Compounds, methods, uses, compositions, kits and packages for the prevention and/or treatment of neural injury or a neurodegenerative disease, based on the use of a retinoic acid derivative, such as fenretinide, and/or analogs, derivatives, pro-drugs, precursors thereof, and/or salts thereof, are described.

PROCESS TO FIND COMPOSITES THAT ARE ADJUSTED FOR THE TREATMENT AND/OR PROPHYLAXIS OF THE OBESIDADE

Method of identifying compounds suitable for treatment and/or prophylaxis of obesity

A method for the discovery of compounds suitable for the treatment and/or prophylaxis of obesity, in which the ability of the test compounds to inhibit de novo lipogenesis in mammals and/or man is determined. The use of compounds which are capable of inhibiting de novo lipogenesis in mammals, and which are substantially free of effects directed towards the CNS, for the preparation of pharmaceutical compositions for the treatment and/or prophylaxis of obesity, as well as for the treatment and/or inhibition of obesity, are also described.

BENZIMIDAZOLONE DERIVATIVES AND SUBSTITUTED QUINAZOLINONES AS AGONISTS ON HUMAN ORL 1 RECEPTOR

Preparación de compuestos, composiciones farmacéuticas que los comprenden y usos. Reivindicación 1: Compuestos de la fórmula general (1), en donde: R1 representa H, alquilo C1-6, alquil(C1-3)-cicloalquilo(C3-6), carbalcoxi (C2-7) o acilo (C2-7); [ ]m simboliza -(CH2)m- en donde m es 0 ó 1; R2 representa halógeno, CF3, alquilo (C1-6), alquil(C1-3)-cicloalquilo(C3-6), fenilo, amino, aminoalquilo(C1-3), alquil(C1-3)-amino dialquil(C1-3)-amino, ciano, cianoalquilo(C1-3), hidroxi, hidroxialquilo (C1-3), alcoxi (C1-3), OCF3, acilo (C2-7), trifluoroacetilo, aminocarboxilo, alquil (C1-3)-sulfonilo o trifluorometilosulfonilo, y n es un entero de 0-4, con la condición de que cuando n es 2, 3 ó 4, los sustituyentes R2 pueden ser iguales o diferentes; A es un anillo saturado o parcialmente insaturado, [ ]o y [ ]p representan -(CH2)o- y -(CH2)p- respectivamente, con la condición de que también el significado -CH- es posible cuando A es un anillo parcialmente insaturado, y o y p independientemente son ...

Pharmaceutical with novel imidazol-1-yl-link

Yeni üre türevleri.

NEW UREA DERIVATIVE AND ITS PRODUCTION

PROBLEM TO BE SOLVED: To produce the subject new compound having a structure in which one of the N atoms is a constituent component of a piperazine ring and the other N atom is substituted with benzylaminoethyl group and useful for treating dysfunction of a gastrointestinal tract and inflammatory disorders. SOLUTION: This new compound is a compound represented by formula I (R1 is H or a lower alkyl; R2 is H or a halogen; R3 is H or a lower alkoxy) and its physiologically acceptable acid addition salt, e.g. (2R)-1-[3,5-bis(trifluoromethyl)benzoyl]-2-(1H-indol-3-ylmethyl)-4-{2-[N-(2-methoxybenzyl) aminoethyl]-aminocarbonyl}piperazine. The compound represented by formula I is produced by reacting a compound represented by formula II with a reactive carbonyl compound represented by formula III (Y is a leaving group of a primary amine or a secondary amine capable of carrying out nucleophilic substitution), providing a carbamoyl compound and then reacting the resultant compound with a compound ...

Method for locating compounds which are suitable for treatment and/or prophylaxis of obesity

The invention relates to a method for locating compounds which are suitable for the treatment and/or prophylaxis of obesity, whereby the ability of the examined compounds to inhibit de novo lipogenasein mammals and/or humans is determined. Also disclosed is the use of compounds which are capable of inhibiting de novo lipogenase in mammals in the production of medicaments for the treatment and/orphophylaxis of obesity.

ALKYLAMINOALKYLAMINE AND ETHERIFYING COMPOUNDS AND PROCESS FOR PREPARING SAME AND INTERMEDIATES AND PHARMACEUTICALS CONTAINING SAME

PERFLUOROKETONE COMPOUNDS AND USES THEREOF

Novel perfluoroketone compounds of formula [I] and [Ia] are described. Also described are uses thereof, such as for inhibition of phospholipase A2 activity. Therapeutic uses thereof are also described, such as for the treatment of neural conditions and/or inflammatory conditions, such as demyelinating (e.g., multiple sclerosis) and neural injury (e.g., spinal cord injury).

PHENLALKYLAMINOALKYL COMPOUNDS, THEIR PRODUCTION AND MEDICAMENT CONTAINING THESE COMPOUNDS

PURPOSE: To provide novel phenylalkylaminoalkyl compds. which protect the mucous membranes of gastrointestinal areas, have an excellent effect for suppressing a ulcer and simultaneously good compatibility and low toxicity and have an effective analgessic characteristic within the gastrointestinal areas. CONSTITUTION: The compd. of formula I [(m) is 1 to 4; (n) is 2 to 5; R1 is H, alkyl; R2 is H, alkyl, alkoxy, halogen, CF3; R3 is H, alkyl, alkoxy, halogen or alhylenedioxy together with R2, R3 and adjacent carbon atoms; R4 is 10C satd. monocyclic or bicyclic tenpene hydrocarbon, formula II; Z is O, N-R5 (R5 is alkyl), S when R4 is formula II] and its physiologically acceptable acid addition salt; for example, N-(2-[[(1S,2S,5S)-6,6-dimethylbicyclo[3,1,1]hepto-2-yl]- methoxy]ethyl]-N-(phenetyl)-N-metylamine. The compd. of the formula I is obtd. by bringing, for example, the compd. of formula III (Q is NHR1) into reaction with the compd. of formula IV (Q' is a dissociation group, etc.). COPYRIGHT ...

Method of preparing pharmaceutical compositions

A method for the discovery of compounds suitable for the treatment and/or prophylaxis of obesity, in which the ability of the test compounds to inhibit de novo lipogenesis in mammals and/or man is determined. The use of compounds which are capable of inhibiting de novo lipogenesis in mammals, and which are substantially free of effects directed towards the CNS, for the preparation of pharmaceutical compositions for the treatment and/or prophylaxis of obesity, as well as for the treatment and/or inhibition of obesity, are also described.

1-[1-(hetero) aryl-1-perhydroxyalkylmethyl]-piperazine compound, preparation thereof and pharmaceutics containing it

NEW COMPOSITES OF 1- [1- (HETERO) ARIL-1-PERHYDROXIALQUILMETIL] - PIPERAZINA, PROCESS FOR ITS PREPARATION AND MEDICINES THAT WILL COUNT THESE COMPOSITES

Hydronopol derivatives as agonists on human ORL1 receptors

The invention relates to a group of hydronopol derivatives which are agonists on human ORL1 (nociceptin) receptors. The invention also relates to the preparation of these compounds, to pharmaceutical compositions containing a pharmacologically active amount of at least one of these novel hydronopol derivatives as an active ingredient, as well as to the use of these pharmaceutical compositions for the treatment of disorders in which ORL1 receptors are involved. The invention relates to compounds of the general formula (1) wherein the symbols have the meanings as given in the description.

7-PHENYL-1,4-DIAZEPANE-DERIVATIVE, MEDICINE CONTAINING THE SAME, ITS PRODUCTION AND STARTING SUBSTANCE FOR PRODUCING THE SAME

PROBLEM TO BE SOLVED: To obtain a new compound having good compatibility and an action distribution suitable for treating functional disorders and inflammatory disorders in gastrointestinal tracts by substituting the 4-position with a carbonyl group having a specific group. SOLUTION: A compound (salt) of formula I {R1 is H, a lower alkyl; R2-R5 are each H, a lower alkyl or the like; R6, R7 are each a lower alkyl, a halogen or the like; A is (CH2)n group [(n) is 1-3] or the like; B is a (substituted) 1-3C alkylene chain). For example, 1-(3,5-bistrifluoromethylbenzoyl)-4-{[3-[N-(2- methoxybenzyl)-N-methyl]amino]-propylcarbonyl}-7-phenyl-1,4-diazepane. The compound of formula I is obtained by a conventional method comprising reacting a compound of formula II (R101 is a lower alkyl, an amino-protecting group) with a compound of formula III and used for forming an amide group by an aminoacylation reaction, and, if necessary, subsequently separating the amino-protecting group R101. COPYRIGHT: ...

ALKYLAMINOALKYLAMINE-AND-ETHER COMPOUND, ITS PRODUCTION AND ANALGESIC MEDICINE FOR GASTROINTESTINAL TRACT CONTAINING THE SAME

PURPOSE: To provide a novel alkylaminoalkylamine- and -ether compd. which exhibits an effective analgesic characteristic in the gastrointestinal tracts, have good compatibility and low toxicity and have the characteristics to protect the stomach and intestines and to protect tumor. CONSTITUTION: The compd. of formula I [(n) is 2 to 5; (m) is 2 to 6; R1 is H, alkyl; R2 is OR4 (R4 is alkyl, phenyl, phenylalkyl), formula II (R5, R6 are H, alkyl, phenyl, phenylalkyl, R5 and R6, together with adjacent N, form a heterocycle, etc.); R3 is 10C satd. monocyclic or bicyclic terpene hydrocarbon, formula III; Z is O, S (when R3 is formula III)] or its physiologically acceptable acid addition salt; for example, N-(2-[(1R,3R,4S)-1-methyl-4-isopropylcyclohexy-3- yloxy)-ethyl]-N-[2-(morpholine-1-yl)-ethyl]-N-methylamine. The compd. in which R1 is alkyl in the formula I is obtd. by bringing, for example, the compd. of formula IV (X is a dissociation group) into reaction with the compd. of formula V. COPYRIGHT ...

1-[1-(HETERO)ARYL-1-PERHYDROXYALKYLMETHYL]-PIPERAZINE COMPOUND, METHOD FOR PRODUCING THE SAME, USE OF THE COMPOUND FOR PRODUCTION OF PHARMACEUTICAL COMPOSITION AND STARTING COMPOUND FOR PRODUCING THE COMPOUND

PROBLEM TO BE SOLVED: To provide a new compound having tachykinin receptor antagonistic action. SOLUTION: The new tachykinin receptor antagonistic compound is a new 1-[1-(hetero)aryl-1-perhydroxyalkylmethyl]-piperazine compound of general formula I [the definitions of R6, R7, A and Z are described in the specification]. The invention further relates to a medicine containing the compound, a method for the production of the compound and an intermediate compound formed in the production process. COPYRIGHT: (C)2003,JPO ...

PITCHABLE WINGLET FOR A WIND TURBINE ROTOR BLADE

A rotor blade for a wind turbine is disclosed. The rotor blade may include a blade root, a blade tip and a body. The body may include a base portion extending from the blade root and a winglet extending from the base portion to the blade tip. In addition, at least a portion of the winglet may be configured to be pitched independent of the base portion. 1. A rotor blade for a wind turbine , the rotor blade comprising:a blade root;a blade tip; and,a body, said body including a base portion extending from said blade root and a winglet extending from said base portion to said blade tip,wherein at least a portion of said winglet is configured to be pitched independent of said base portion.2. The rotor blade of claim 1 , wherein said winglet defines a pitch axis oriented at an angle relative to a pitch axis of said base portion claim 1 , said winglet being configured to be pitched about said pitch axis.3. The rotor blade of claim 1 , further comprising a pitch adjustment mechanism coupled to said winglet claim 1 , said pitch adjustment mechanism being configured to pitch said winglet.4. The rotor blade of claim 3 , wherein said pitch adjustment mechanism comprises a motor coupled to said winglet.5. The rotor blade of claim 4 , wherein said winglet comprises a first portion coupled to said base portion and a second portion coupled to said first portion at a pitch joint claim 4 , said motor being coupled to said second portion such that said second portion is pitched at said pitch joint.6. The rotor blade of claim 3 , wherein said pitch adjustment mechanism comprises a first rod extending adjacent to a leading edge of said winglet and a second rod extending adjacent to a trailing edge of said winglet claim 3 , said first and second rods being configured to be actuated so as to pitch said winglet.7. The rotor blade of claim 6 , wherein said winglet comprises a flexible sleeve coupled to said base portion claim 6 , said first and second rods being configured to pitch said ...

ROTOR BLADE ASSEMBLY AND METHOD FOR ADJUSTING LOADING CAPABILITY OF ROTOR BLADE

A rotor blade assembly and a method for adjusting a loading capability of a rotor blade are disclosed. The rotor blade assembly includes a rotor blade having surfaces defining a pressure side, a suction side, a leading edge, and a trailing edge extending between a tip and a root. The rotor blade further defines a span and a chord. The rotor blade assembly further includes a spoiler assembly operable to alter a flow past a surface of the rotor blade. The spoiler assembly is incrementally deployable from the surface along one of a length or a width of the spoiler assembly. 1. A rotor blade assembly , comprising:a rotor blade having surfaces defining a pressure side, a suction side, a leading edge, and a trailing edge extending between a tip and a root, the rotor blade further defining a span and a chord; and,a spoiler assembly operable to alter a flow past a surface of the rotor blade, the spoiler assembly incrementally deployable from the surface along one of a length or a width of the spoiler assembly.2. The rotor blade assembly of claim 1 , wherein the spoiler assembly comprises a spoiler and an actuator.3. The rotor blade assembly of claim 2 , wherein the spoiler assembly further comprises a plurality of spoilers.4. The rotor blade assembly of claim 2 , wherein the spoiler assembly further comprises a plurality of actuators.5. The rotor blade assembly of claim 1 , wherein the spoiler assembly is incrementally deployable along the span.6. The rotor blade assembly of claim 5 , wherein the spoiler assembly is incrementally deployable from an inboard end to an outboard end.7. The rotor blade assembly of claim 1 , further comprising a controller in operable communication with the spoiler assembly.8. The rotor blade assembly of claim 1 , wherein the spoiler assembly is positioned adjacent the leading edge.9. The rotor blade assembly of claim 1 , wherein the spoiler assembly is deployable from the suction side.10. A wind turbine claim 1 , comprising:a plurality of rotor ...

Alumina Forming Bimetallic Tube for Refinery Process Furnaces and Method of Making and Using

Provided is a bimetallic tube for transport of hydrocarbon feedstocks in refinery process furnaces, and more particularly in furnace radiant coils, including: i) an outer tube layer being formed from stainless steels including chromium in the range of 15.0 to 26.0 wt. % based on the total weight of the stainless steel; ii) an inner tube layer being formed from an alumina forming bulk alloy including 5.0 to 10.0 wt. % of Al, 20.0 wt. % to 25.0 wt. % Cr, less than 0.4 wt. % Si, and at least 35.0 wt. % Fe with the balance being Ni, wherein the inner tube layer is formed plasma powder welding the alumina forming bulk alloy on the inner surface of the outer tube layer; and iii) an oxide layer formed on the surface of the inner tube layer, wherein the oxide layer is substantially comprised of alumina, chromia, silica, mullite, spinels, or mixtures thereof. 1. A bimetallic tube for the transport of hydrocarbon feedstocks through the radiant coils of refinery process furnaces , comprising:i) an outer tube layer being formed from stainless steels comprising chromium in the range of 15.0 to 26.0 wt. % based on the total weight of the stainless steel;ii) an inner tube layer being formed from an alumina forming bulk alloy comprising 5.0 to 10.0 wt. % of Al, 20.0 wt % to 25.0 wt. % Cr, less than 0.4 wt. % Si, and at least 35.0 wt. % Fe with the balance being Ni, wherein the inner tube layer is formed by plasma powder welding the alumina forming bulk alloy on the inner surface of the outer tube layer; andiii) an oxide layer formed on the surface of the inner tube layer, wherein the oxide layer comprises alumina, chromia, silica, mullite, spinels, or combinations thereof.2. The bimetallic tube o claim 1 , wherein the stainless steel of the outer tube layer includes chromium in the range of 15.0 to 20.0 wt. % based on the total weight of the stainless steel.3. The bimetallic tube of claim 1 , wherein the stainless steel of the outer tube layer includes chromium in the range of 16.0 ...

Method and Apparatus for Placement and Routing of Partial Reconfiguration Modules

A method for designing a system on a target device includes assigning resources on the target device to static logic modules and partial reconfigurable (PR) modules in the system. The instances of one of the PR modules are placed and routed in parallel utilizing resources from those that are assigned. Other embodiments are also disclosed.

SYSTEM AND METHOD FOR ENHANCING CORROSION RATE DETERMINATION IN PROCESS EQUIPMENT USING A TELESCOPING/ROTATING SENSOR

A system and method for optimizing the response of a metal loss sensor which is configured in a way that its insertion depth and orientation in the process fluid are adjustable. These adjustments affect local turbulence and thereby enable achieving a desired corrosion rate at the metal loss sensor. Corrosion rate comparison between the metal loss sensor and pressure containment boundary can be measured directly or indirectly by computing wall shear stresses at the sensor and the pressure containment boundary. 1. A method for adjusting the metal loss rate of a metal loss sensor installed adjacent a pressure containment boundary in one of a piping and a process unit that is exposed to a fluid flow of a corrosive fluid comprising:measuring the corrosion rate of the metal loss sensor installed adjacent the pressure containment boundary;relating the corrosion rate at the metal loss sensor to the corrosion rate at the pressure containment boundary; andadjusting the position of the metal loss sensor with respect to the fluid to achieve a desired relationship between the corrosion rate at the metal loss sensor and the pressure containment boundary.2. The method of wherein the relating the corrosion rates is accomplished by determining the wall shear stress associated with the flow turbulence.3. The method of wherein the relating the corrosion rates is accomplished by a direct measurement of the corrosion rate at the pressure containment boundary.4. The method of wherein the wall shear stress is determined using computational fluid dynamics.5. The method of wherein the direct measurement of the pressure containment boundary is made using nondestructive testing.6. The method of wherein the direct measurement of the pressure containment boundary is made using coupons fixed to the pressure containment boundary.7. The method according to claim 1 , wherein said metal loss sensor is a mechanical oscillator.8. The method according to claim 1 , wherein the fluid flow is stagnant.9. ...

METHOD FOR QUANTIFYING CORROSION AT A PRESSURE CONTAINING BOUNDARY

A method for determining the amount and rate of corrosion which has occurred on the surface of a process unit by measuring corrosion with a corrosion sensor and measuring at least one parameter inside the process unit. Corrosion on the internal surfaces of a process unit can then be determined. 1. A method for determining the amount of corrosion which has occurred on an interior surface of a process unit due to a corrosive fluid comprising:(a) determining the corrosion that has occurred on a corrosion sensor, that is located within the corrosive fluid within the process unit, and(b) relating the corrosion of the corrosion sensor to the amount of corrosion which has occurred on at least one point on a surface of the process unit.2. The method of wherein said one point on a surface of the process unit is an interior wall of a pressure containment boundary.3. The method of wherein said one point is an interior wall of a pipe.4. The method of wherein said corrosion sensor is a mechanical oscillator.5. The method of wherein said corrosion sensor is a tuning fork having a resonance frequency.6. The method of wherein said corrosion sensor outputs an electrical signal.7. The method of wherein step of relating the corrosion of the sensor to that of the wall is performed by relating a change in the resonance frequency of the tuning fork to the corrosion of the pressure containment boundary.8. The method of wherein the step of relating the corrosion of the sensor to that of the pressure containment boundary is performed by determining the weight loss of the sensor.9. The method of wherein the corrosion of the corrosion sensor is related to corrosion of a coupon fixed to the pressure containment boundary of a process unit.10. The corrosion of wherein the corrosion of the coupon is determined by weight loss.11. The method of wherein the step of relating the corrosion of the corrosion sensor to the corrosion at the pressure containing boundary is performed by relating the weight ...

ROTOR BLADE ASSEMBLY FOR WIND TURBINE

A rotor blade assembly is disclosed. The rotor blade assembly includes a rotor blade having exterior surfaces defining a pressure side, a suction side, a leading edge, and a trailing edge extending between a tip and a root. The rotor blade further defines a span and a chord. The rotor blade includes a skin layer that includes the exterior surfaces. The rotor blade assembly further includes a passive spoiler assembly operable to alter a flow past an exterior surface of the rotor blade. The spoiler assembly includes a spoiler feature movable between a non-deployed position and a deployed position. Movement of the spoiler feature from the non-deployed position to the deployed position is caused by a change in an applied force to the spoiler feature by the skin layer. 1. A rotor blade assembly , comprising:a rotor blade having exterior surfaces defining a pressure side, a suction side, a leading edge, and a trailing edge extending between a tip and a root, the rotor blade further defining a span and a chord, the rotor blade comprising a skin layer that includes the exterior surfaces; and,a passive spoiler assembly operable to alter a flow past an exterior surface of the rotor blade, the spoiler assembly comprising a spoiler feature movable between a non-deployed position and a deployed position,wherein movement of the spoiler feature from the non-deployed position to the deployed position is caused by a change in an applied force to the spoiler feature by the skin layer.2. The rotor blade assembly of claim 1 , wherein the applied force is a compressive force.3. The rotor blade assembly of claim 1 , wherein an exterior surface of the spoiler feature in the non-deployed position is generally flush with the exterior surfaces of the rotor blade.4. The rotor blade assembly of claim 1 , wherein a first end of the spoiler feature is coupled to the skin layer.5. The rotor blade assembly of claim 1 , wherein the spoiler assembly further comprises a biasing element providing a ...

Network-Based Resource Configuration Discovery Service

A network-based discovery system and service are disclosed that provide client discovery services to a number of clients over a network. The network-based discovery system includes a database that stores discovery information of client network-based resource configurations. The discovery information may be obtained from client resources by client-side discovery components that are placed on client resources, obtain the discovery information and that send the information to the discovery system. The discovery system analyzes the discovery information to determine the client network-based resource configurations and generates client network-based resource configuration representations for the respective clients. The client network-based resource configuration representation may include a description of, and dependencies among, a plurality of computer-based resources. The discovery service may operate across a client network that spans both of a client's enterprise data networks as well as resources that are operated on behalf of the same client by a service provider network. 121.-. (canceled)22. A system , comprising: obtain discovery information about a client network-based resource configuration of a client of the provider network; and', 'generate a representation of the network-based resource configuration of the client based on the discovery information; and, 'a discovery service of a provider network, the discovery service configured to generate a migration plan recommendation based at least in part on the representation of the network-based resource configuration of the client, wherein the migration plan recommendation specifies a plan to migrate at least a portion of the network-based resource configuration of the client from the client network to the provider network; and', 'execute a migration plan that is based at least in part on the migration plan recommendation to migrate the at least a portion of the network-based resource configuration of the client ...

APPLICATION MIGRATION SYSTEM

At a network-accessible service, a request is received from a client to enable access by a migration facilitator to a configuration record collection of the client. A response to a migration candidate identification query is generated using the configuration record collection and transmitted to the facilitator. An indication of a proposal associated with migrating at least a portion of the client's computing environment to a different computing environment with assistance from the facilitator is provided to the client. 122.-. (canceled)23. A computer-implemented method , comprising:discovering a first application component being executed at a first premise external to a cloud computing environment;detecting a relationship between the first application component and a second application component being executed at the first premise, wherein the detecting is based on analysis of a data set collected from at least the first application component that indicates a dependency between the first and second application components; andcausing a migration of the first and second application components from the first premise to the cloud computing environment, wherein the migration is initiated based at least in part on the detected relationship.24. The computer-implemented method as recited in claim 23 , wherein the data set comprises network port data.25. The computer-implemented method as recited in claim 23 , wherein the data set comprises identifiers of one or more processes.26. The computer-implemented method as recited in claim 23 , wherein the first premise comprises a premise of a different cloud computing environment.27. The computer-implemented method as recited in claim 23 , wherein the first application component includes a portion of a particular tier of a multi-tier web application claim 23 , and wherein the second application component includes a portion of another tier of the multi-tier web application.28. The computer-implemented method as recited in claim 23 ...

Safety-enhanced needle-free injector

A method for needle-free injection and a needle-free injector device are provided. The method includes automatically injecting an injectable into a surface in contact with the needle-free injector in response to a skin compression parameter of an end of the needle-free injector. A needle-free injector device ( 102 ) includes predefined structures formed on it to inject an injectable through a non-porous material. The predefined structures engage an airlock mechanism such that an airlock in the non-porous material and operably coupled to the airlock mechanism can only be opened and closed to enable needle-free injection through the non-porous material without disrupting an integrity of the non-porous material by the needle-free injector device. Other functions, embodiments and methods for using and programming the needle-free injector device are also provided.

Fiber sampler for recovery of bioaerosols and particles

A bioparticle collection device and an aerosol collection system. The bioparticle collection device includes a collection medium including a plurality of fibers formed into a fiber mat and configured to collect bioparticles thereon, and includes a viability enhancing material provider disposed in a vicinity of the plurality of fibers and configured to provide a viability enhancing material to the collected bioparticles to maintain viability of the bioparticles collected by the fiber mat. The aerosol collection system includes an aerosol pumping device configured to entrain particles in an gas stream, an aerosol saturation device configured to saturate the particles in the gas stream with a biocompatible liquid, and an aerosol collection medium downstream from the aerosol saturation device and including a plurality of fibers formed into a fiber mat for collection of the saturated aerosol particles.

Protection of Channel Connections in an Optical Network

An optical end terminal in which protection switching is implemented by using (i) the optical data receiver thereof for detecting a path failure and (ii) the optical data transmitter thereof for signaling the detected path failure to the protection-switching circuit. In an example embodiment, the optical data receiver is configured to detect a path failure based on the presence of certain data-recovery errors. The optical data transmitter is operatively connected to the optical data receiver and configured to generate an in-band dither tone of a predetermined frequency in response to such failure detection. The protection-switching circuit is configured to (i) detect dither tones in the optical signals passing therethrough and (ii) connect the optical data receiver to the protection path instead of the working path in response to detecting the dither tone of the predetermined frequency.

Network-Based Resource Configuration Discovery Service

A network-based discovery system and service are disclosed that provide client discovery services to a number of clients over a network. The network-based discovery system includes a database that stores discovery information of client network-based resource configurations. The discovery information may be obtained from client resources by client-side discovery components that are placed on client resources, obtain the discovery information and that send the information to the discovery system. The discovery system analyzes the discovery information to determine the client network-based resource configurations and generates client network-based resource configuration representations for the respective clients. The client network-based resource configuration representation may include a description of, and dependencies among, a plurality of computer-based resources. The discovery service may operate across a client network that spans both of a client's enterprise data networks as well as resources that are operated on behalf of the same client by a service provider network.

Accelerated thermal mitigation for multi-core processors

A temperature sensor may sense the temperature of a multi-core processor. In response to the temperature of the multi-core processor exceeding a temperature threshold for the multi-core processor, one or more busy processor cores of the multi-core processor may be power collapsed without reducing clock speed of the multi-core processor.

Testing apparatus for cured liners used in pipeline rehabilitation

A testing apparatus for onsite creation of cured sample liners necessary for confirming proper rehabilitation of pipelines includes a testing box having a base with a plurality of upstanding side walls defining an open upper end of the testing box. The testing box also includes an electrical power control assembly and an ultraviolet light assembly. A liner support manifold is shaped and dimensioned for supporting a sample liner and for attachment to the open upper end of the testing box for exposing the sample liner to pressure and ultraviolet light. In practice, and with the sample liner secured to the liner support manifold and the liner support manifold secured to the testing box, the sample liner is exposed to pressure and UV light in a highly controlled manner allowing for replication of actual in-line curing processing.

System and method of session key generation and exchange

Computer-implemented methods and systems reliant on establishing a common session key between an electronic device and a computer server are disclosed. The method and systems may be for processing de-tokenization requests in payment transaction processing and for preparing an electronic device to perform payment transactions. During such a transaction, the server may perform a method that includes receiving a de-tokenization request including a payment token and a cryptogram generated by the electronic device using a session key generated by the electronic device based on a fingerprint of the electronic device, a secret value previously shared with the electronic device, the payment token, and a transaction counter; retrieving the fingerprint, the secret value, and the transaction counter and generating the session key based on the same; verifying the cryptogram using the session key; retrieving an associated account number; and sending response to the request including the account number.

Systems and methods for intelligent responses to queries based on trained processes

Systems and methods are provided that use a trained process to reply to a request comprising query data defining a query and context data defining contextual factors for the query from a device. The query is answered by one or more selected APIs of a plurality of APIs that invoke respective services to prepare a response. The trained process determines an execution plan responsive to the query data and the context data and is configured using training to define execution plans comprising selected APIs where a particular API is selected for the plan if it answers at least a portion of the query and the selected APIs together prepare the response optimized for the device according to the context data. The plan is provided to an execution component to execute the plan using the selected APIs and send the response to the requesting device.

Method and apparatus for correcting geometric and optical aberrations in augmented reality

The disclosed technology teaches an AR calibration system for compensating for AR headset distortions. A calibration image is provided to an external screen and viewable through a headset reflector, and an inverse of the calibration image is provided to a headset display, reflected off the reflector and observed by a camera of the system while it is simultaneously observing the calibration image on the external screen. The camera is located to represent a user's point of view and aligned to observe the inverse calibration image projected onto the reflector. A distortion mapping transform is created using an algorithm to search through projection positions of the inverse calibration image until the inverse image observed by the camera cancels out an acceptable portion of the calibration image provided to the external screen as observed through the reflector by the camera, and the transform is used by the headset, to compensate for distortions.

HIGH PERFORMANCE FIRED HEATER TUBES

Fired heater tubes with improved resistance to corrosion and fouling suitable for use in thermal processing units of petroleum refineries and petrochemical plants are fabricated from a bulk alloy of an alumina-forming alloy which is capable of forming a stable oxide film on the surfaces of the tubes. The bulk alloy comprising about 3 wt. % to about 20 wt. % of Al, about 5 wt. % to about 30 wt. % Cr and at least one alloying component selected from Fe, Ni, Co, Si, Mn, B, C, N, P, Ga, Ge, As, In, Sn, Sb, Pb, Sc, La, Y, Ce, Ti, Zr, Hf, V, Nb, Ta, Mo, W, Re, Ru, Rh, Ir, Pd, Pt, Cu, Ag, Au and mixtures of these components. 1. A fired heater tube having an inner surface and an outer surface formed from an alumina-forming bulk alloy comprising about 3 wt. % to about 20 wt. % of Al , about 5 wt. % to about 30 wt. % Cr and at least one element selected from the group consisting of Fe , Ni , Co , Si , Mn , B , C , N , P , Ga , Ge , As , In , Sn , Sb , Pb , Sc , La , Y , Ce , Ti , Zr , Hf , V , Nb , Ta , Mo , W , Re , Ru , Rh , Ir , Pd , Pt , Cu , Ag , Au and mixtures thereof , the tube having a surface oxide layer on at least one of its alumina-forming bulk alloy surfaces , substantially comprised of alumina , chromia , silica , mullite , spinels , or mixtures thereof.2. The fired heater tube of in which the surface oxide layer is formed on the inner surface of the tube.3. The fired heater tube of in which the oxide layer is alumina.4. The fired heater tube of in which the alumina forming bulk alloy comprises about 3 wt. % to about 10 wt. % of aluminum.5. The fired heater tube of in which the alumina forming bulk alloy comprises about 3 wt. % to about 3.5 wt. % of aluminum.6. The fired heater tube of in which the alumina forming bulk alloy comprises about 1 wt. % to about 3 wt. % of niobium.7. The fired heater tube of in which the alumina forming bulk alloy comprises about 10 wt. % to about 20 wt. % of chromium.8. The fired heater tube of in which the alumina forming bulk ...

Curved nanofiber products and applications thereof

A filtration device including a contoured support having 1) an interior surface, 2) an outside peripheral surface spaced farther from a center of the contoured support than the interior surface, and 3) a rim enclosed and sealed to a perimeter of the contoured support. The filtration device includes macroscopic openings in the contoured support extending from the interior surface to the outside peripheral surface, and a plurality of nanofibers having diameters less than 1 micron. The nanofibers are disposed on the outside peripheral surface of the contoured support, and cover the macroscopic openings to form a filtration medium on the contoured support.

Sevelamer for the treatment and/or prevention of aortic stenosis

A method of treating and/or preventing aortic stenosis in a patient in need thereof comprises administering to the patient a therapeutically effective amount of sevelamer or a pharmaceutically acceptable derivative, mixture or salt thereof (e.g. sevelamer hydrochloride or sevelamer carbonate). The method may attenuate or arrest the deposition of calcium phosphate crystals on the aortic valve of the patient. The method is applicable to patients who do not have hyperphosphatemia, including those having a serum phosphate level of 2.5 mg/d L to 4.5 mg/d L.

Multi-user multi-touch projected capacitance touch sensor with event initiation based on common touch entity detection

Techniques for providing multi-user multi-touch projected capacitive touch sensors are disclosed herein. Some embodiments may include a method that includes receiving a first sense signal from a first sensing array, the first sensing array configured to provide the first sense signal indicating a first touch on a first touch surface of a touch substrate as well as receiving a second sense signal from a second sensing array, the second sensing array configured to provide the second sense signal indicating a second touch on a second touch surface of a second touch substrate occurring concurrently to the first touch. The method may further include determining whether the first touch and the second touch share at least one anti-ghost. The method may also include associating the first touch and the second touch with a common touch entity in response to determining that the first touch and the second touch share the at least one anti-ghost.

Managing Changes to Shared Electronic Documents Using Change History

Embodiments are disclosed for a system to manage changes to a shared electronic document. In embodiments, a client side method is used to manage changes to a shared electronic document. The method includes receiving a change to a locally stored rendition of a shared electronic document, and updating a change history. In embodiments, the change history captures the change made to the locally stored rendition of a shared electronic document. The method also includes sending information regarding the change to a server, receiving information regarding a master copy of the shared electronic document, and determining based on the received information the change was accepted by the server and applied to the master copy of the shared electronic document.

Hybrid perovskite bulk photovoltaic effect devices and methods of making the same

The present disclosure relates to a composition that includes a perovskite crystal having a ferroelectric domain aligned substantially parallel to a reference axis. In some embodiments of the present disclosure, the perovskite crystal may include ABX3, where A is a first cation, B is a second cation, and X is an anion. In some embodiments of the present disclosure, A may include an alkyl ammonium cation. In some embodiments of the present disclosure, B may include a metal element. In some embodiments of the present disclosure, the metal element may include lead. In some embodiments of the present disclosure, X may include a halogen. In some embodiments of the present disclosure, the perovskite crystal may include methylammonium lead iodide.

System and method for selectively enabling a data transfer method

A computer system for selectively enabling a data transfer method is disclosed. The computer system includes a processor, a communications module, and a memory. The memory stores instructions that, when executed by the processor, cause the computer system to: receive a signal from a remote electronic device via a network using the communications module, the received signal representing information including a context for a transfer of value between a database record associated with a data sender and a database record associated with a data receiver, the context including an identifier for the data receiver; obtain a condition to be satisfied in performing the transfer of value based on the identifier for the data receiver; determine that the condition is satisfied by performing the transfer of value using a particular data transfer method; and enable the transfer of value using the particular data transfer method.

Dynamic biometric authentication based on distributed ledger data

The disclosed exemplary embodiments include computer-implemented devices, apparatuses, and processes that, among other things, perform dynamic biometric authentication based on distributed ledger data. For example, a device may compute a first hash value based on first biometric data captured by a sensor unit, and may transmit a request to, and receive a response from, a computing system across a communications network via the communications unit. The request may cause the computing system to execute instructions maintained within the distributed ledger data, and to extract second biometric data maintained within an element of the distributed ledger data. The second biometric data may include a second hash, which the computing system may incorporate into the response. The device may authenticate an identity associated with the device when the first hash value corresponds to the second hash value incorporated within the response.

Firearm cover for attachment to a firearm with a scope mounted thereto

A firearm cover for attachment to a firearm with a scope mounted thereto is disclosed herein. The firearm cover may include a barrel cover, a stock cover attached to the barrel cover, and a rotatable hood attached to the stock cover. The rotatable hood may include a first configuration disposed about the scope and a second configuration rotated away from the scope.

Systems and methods for managing a data request interface

A computer system and method for managing a data request interface. The system includes a memory associated with the data request interface and coupled to a processor. The memory includes processor-executable instructions of the method for managing the data request interface. The method includes: receiving, from a first client device, a first signal including a primary authorization credential associated with a data record and a second signal including a request to generate an alternate authorization credential for use by a software module. The alternate authorization credential is associated with data retrieval constraints. The method includes generating the alternate authorization credential and configuring the data request interface to impose the data retrieval constraints for constraining data operations on the data record upon receipt of the alternate authorization credential. The method further includes sending, to the first client device or a second client device, a third signal including the alternate authorization credential.

APPLICATION MIGRATION SYSTEM

At a network-accessible service, a request is received from a client to enable access by a migration facilitator to a configuration record collection of the client. A response to a migration candidate identification query is generated using the configuration record collection and transmitted to the facilitator. An indication of a proposal associated with migrating at least a portion of the client's computing environment to a different computing environment with assistance from the facilitator is provided to the client. 1. A system , comprising:one or more computing devices of a resource migration marketplace service of a provider network; receive, via one or more programmatic interfaces, a first request from a first client to enable access by one or more migration facilitators to a configuration record collection of the first client, wherein the configuration record collection is stored at a configuration discovery service, wherein the configuration record collection is associated with a first computing environment of the first client, and wherein the first computing environment comprises at least one resource outside the provider network;', 'transmit, via the one or more programmatic interfaces to a particular migration facilitator of the one or more migration facilitators, a response generated at the configuration discovery service to a particular migration candidate identification query, wherein the response is based at least in part on the configuration record collection;', 'receive, from the particular migration facilitator via the one or more programmatic interfaces, an indication of a first proposal associated with migrating at least a portion of the first computing environment to a second computing environment, wherein the second computing environment comprises at least one resource of the provider network, and wherein the first proposal includes a preliminary cost metric; and', 'transmit, via the one or more programmatic interfaces to the first client, ...

POLYOLEFINE

Method and apparatus for wind turbine braking

A method for braking a wind turbine (10) including at least one rotor blade (24) coupled to a rotor (18). The method includes selectively controlling an angle of pitch of the at least one rotor blade with respect to a wind direction based on a design parameter of a component of the wind turbine to facilitate reducing a force induced into the wind turbine component as a result of braking.

Self-contained swab-based diagnostic systems

A diagnostic test unit is provided. The test unit comprises a stem having a first end and a second end, the stem defining at least one flow channel extending between the first end and the second end. A swab is disposed at the first end of the stem, the swab being configured to collect a test sample derived from a biological source that is suspected of containing an analyte. The test unit also comprises a fluid chamber configured to contain a fluid, wherein the fluid chamber is in fluid communication with the swab via the flow channel. The test unit also comprises a rupturable seal that inhibits leakage of the fluid from the fluid chamber prior to use, and an assay for detecting the presence or absence of the analyte. The assay is in fluid communication with the swab, the flow channel, and the fluid chamber.

Optical detection system using electromagnetic radiation to detect presence or quantity of analyte

A system that employs transmission-based detection techniques to determine the presence or concentration of an analyte within a test sample is provided. Specifically, the optical detection system contains a chromatographic-based assay device that is positioned in the electromagnetic radiation path defined between an illumination source and detector. To enhance the sensitivity and signal-to-noise ratio of the system without significantly increasing costs, the distance between the illumination source and/or detector and the assay device is minimized. The illumination source and/or detector may also be positioned directly adjacent to the assay device. In addition, the system may be selectively controlled to reduce reliance on external optical components, such as optical filters or diffusers.

Electroluminescent illumination source for optical detection systems

An optical detection system that utilizes an electroluminescent (EL) illumination source is provided. Unlike illumination sources used with some conventional optical detection systems, an EL device is relatively homogeneous and diffuse, and thus may provide uniform illumination to the test sample. In addition, the emitted light intensity of the EL device may be easily controlled by simply varying the voltage or the frequency of the applied current. The relatively flexibility of EL devices may also allow them to be readily incorporated into a chromatographic-based assay device for detecting the presence or absence of an analyte within a test sample.

Verfahren zur Polymerisation von Äthylen

MOLECULAR WEIGHT REGULATION IN OLEFIN POLYMERIZATION

OLEFINENPOLYMERISATION

Object detection and tracking with variable-field illumination devices

Imaging systems and methods optimize illumination of objects for purposes of detection, recognition and/or tracking by tailoring the illumination to the position of the object within the detection space. For example, feedback from a tracking system may be used to control and aim the lighting elements so that the illumination can be reduced or increased depending on the need.

Apparatus and methods for separating agglutinants and disperse particles

Rotating apparatus has a separation zone structure having solid components spaced apart to form gaps. The gaps are large enough to allow disperse particles to change position relative to the center of rotation by passing through the separation zone structure. The gaps are too small to allow particle agglutinants to pass through the separation zone structure.

Method of increasing grafting efficiency in graft copolymerization

Electrical connector

Method and apparatus for constructing a networking database and system

A networking database containing a plurality of records for different individuals in which individuals are connected to one another in the database by defined relationships. Each individual has the opportunity to define the relationship which may be confirmed or denied. E-mail messaging and interactive communication between individuals and a database service provider provide a method of constructing the database. The method includes having a registered individual identify further individuals and define therewith a relationship. The further individuals then, in turn, establish their own defined relationships with still other individuals. The defined relationships are mutually defined.

Method and apparatus for a remote tire pressure monitoring system

A tire characteristic monitoring method allows automatic programming of tire position information in a remote tire pressure monitoring system (10). The method includes, from a remotely located exciter (16) using a primary coil (18) to transmit a relatively low frequency signal to a secondary coil (L1) of a tire monitor (12) associated with a tire of a vehicle. The method further includes the step of, at the tire monitor, in response to the relatively low frequency signal, transmitting a relatively high transmitting signal to convey data. The data are received at the exciter and subsequently loaded into a receiving unit (14) of the vehicle.

METHOD OF MANUFACTURING A MULTI-LAYER PRINTED CIRCUIT BOARD

Vapour barrier

A water meter has a glass window (30) having an aperture (32) through which extends one or more screw threaded terminals (20) enabling electrical connection to be made to an internal electronic encoder. A resilient grommet (34) is positioned in the aperture (32) and is held in compression between inner and outer sealing plates (36, 38). These are drawn together by the terminals which carry nuts.

COATED PHARMACEUTICAL TABLET CONTAINING 1-ACETOXYETHYL ESTER OF CEFUROXIME AND PROCESS FOR PREPARING THE SAME

Wind turbine rotor blade with aerodynamic winglet

Microfluidic assay devices

CONNECTOR ASSEMBLY FOR A FLAT PANEL.

FRAMEWORK FOR THERAPEUTIC USE OF THERAPEUTIC EQUIPMENT (B) BICYCLONES

2.beta.-MORPHOLINO-ANDROSTANE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION

Abstract Compounds having the formula: wherein R1 is H or an optionally substituted acyl group having 1-12 carbon atoms, R2 is H or an acyl group having 1-12 carbon atoms and R3 is C, N-CH3 or a direct bond; and mono- or bisquaternary ammonium compounds thereof and acid addition salts of the non or mono-quaternary ammonium compounds. Process for the preparation of these compounds. Compositions comprising at least one of the above compounds as the active ingredient. The compounds are favourable neuromuscular blocking agents.

System and method for selective regression testing

A system and method for selective regression testing of a software system that determines which test units of a test suite must be re-run after a modification to the software system. The entities which are covered by each test unit are identified. When the software system is modified the entities which were changed by the modification are identified. The test units which need to be re-run are determined by analyzing the change information and the coverage information to select those test units that cover changed entities.

PROCEDURE FOR THE PREPARATION OF CIMETIDINE POLYMORF B.

Network-based resource configuration discovery service

A network-based discovery system and service are disclosed that provide client discovery services to a number of clients over a network. The network-based discovery system includes a database that stores discovery information of client network-based resource configurations. The discovery information may be obtained from client resources by client-side discovery components that are placed on client resources, obtain the discovery information and that send the information to the discovery system. The discovery system analyzes the discovery information to determine the client network-based resource configurations and generates client network-based resource configuration representations for the respective clients. The client network-based resource configuration representation may include a description of, and dependencies among, a plurality of computer-based resources. The discovery service may operate across a client network that spans both of a client's enterprise data networks as well as resources that are operated on behalf of the same client by a service provider network.

COATED PHARMACEUTICAL TABLET CONTAINING 1-ACETOXYETHYL ESTER OF CEFUROXIME AND PROCESS FOR PREPARING THE SAME

Ce comprimé pharmaceutique à propriété antibiotique est destiné à être administré par voie orale et comprend une partie formant son noyau contenant une quantité efficace de céfuroxime axétil (l'ester 1-acétoxyéthylique de la céfuroxime) en tant qu'ingrédient actif et un film d'enrobage qui sert à masquer le goût amer de la céfuroxime axétil lors d'une administration par voie orale, le film d'enrobage ayant un temps de rupture inférieur à 40 secondes et le noyau du comprimé se désintégrant immédiatement après la rupture du film d'enrobage. This antibiotic-proprietary pharmaceutical tablet is intended for oral administration and includes a core portion containing an effective amount of cefuroxime axetil (the 1-acetoxyethyl ester of cefuroxime) as an active ingredient and a film of coating which serves to mask the bitter taste of cefuroxime axetil during oral administration, the coating film having a break time of less than 40 seconds and the core of the tablet disintegrating immediately after the break of the film coating.

System and method for selective regression testing.

Polymerisation process

In a process for the production of aqueous polymer dispersions having a substantial degree of particle size uniformity, active centres are induced in a surface active agent and a monomer capable of radical addition polymeriatizon is subsequently introduced and polymerized in an aqueous medium by means of the active centres to give the aqueous polymer dispersion. The active centres may be induced by ultra violet light in the presence of oxygen, g -rays or chemical initiators such as peroxy compounds e.g. tert. butyl peracetate, potassium persulphate and cumene hydroperoxide, preferably in the presence of oxygen, or redox systems, e.g. ferrous pyrophosphate / hydrogen peroxide / fructose. The surface active agent may be common soap, alkali metal salts of alkyl sulphates, quaternary ammonium halides, e.g. cetylpyridinum chloride and cetyltrimethyl ammonium bromide, and condensates of ethylene oxide with higher alcohols, alkylphenols and mercaptans. Specified monomers are styrene, acrylonitrile, methyl methacrylate, ethyl acrylate, vinyl acetate, vinyl chloride, butadiene, isoprene and mixtures, e.g. of butadiene and styrene. Dispersing agents, e.g. condensates of ethylene oxide with higher alcohols, alkyl phenols, mercaptans or long chain aliphatic amines, may be added with the monomer. The polymerization may be terminated by the addition of hydroquinone or a salt of dimethyl- or diethyl - dithiocarbamic acid, or the reaction may be allowed to proceed to completion followed by the addition of a second monomer to yield block copolymers. The products may be used as coating compositions and for treating paper.

Improved delivery system

Liposome preparation and material encapsulation method

The present invention relates to a method of producing liposomes useful for encapsulating and delivering a wide variety of biologically active materials. The invention provides liposomes and a production method which is simple, feasible and inexpensive for the large-scale commercial manufacturing of liposomes and encapsulated materials. The method involves the formation of a liposome dispersion in the absence of an organic solvent or detergent, one or several cycles of freezing and thawing the liposomes, and dehydration of the liposome dispersion to form a lipid powder. When desired, the lipid powder is hydrated in the presence of the biologically active material whereby the material is encapsulated in reconstituted liposomes. The method can also include combining the liposome dispersion with a bulking agent prior to the dehydration and formation of the lipid powder. The addition of the bulking agent facilitates the handling of the lipid powder as well as its rapid dispersal upon hydration.

Process for the manufacture of multilayer articles

A method and apparatus for manufacturing composite articles such as laminate ballistic protection and structural reinforcements. The method involves placing a composite assembly in a sealable membrane system, e.g. a vacuum bag and placing the vacuum bag in a pressure vessel to apply heat and pressure to the composite assembly, thereby manufacturing a composite article. The apparatus comprises: a pressure vessel; a source of processing liquid to apply isostatic pressure to the vacuum bag; processing liquid heating, cooling, pressurising and circulating means; and a control system to control the heating, cooling and pressurising means. The sealable membrane system may preferably comprise: a sealable membrane to separate the composite article from the processing liquid and maintain the composite article below atmospheric pressure; and a membrane to cushion the composite article and resist adhesion of the article to other membranes. The processing liquid is preferably silicone oil.

Foldable stock assembly

A folding stock assembly for a firearm includes a butt stock portion; a receiver interface portion; and a bidirectional hinge assembly configured to allow the butt stock portion to bidirectionally pivot with respect to the receiver interface portion.

Extensible event-action system

Abstract of the Disclosure An extensible event-action system which permits a user of a computer system to specify actions to be performed in response to combinations of user-defined and/or system events. A user-defined event takes place when a process sends an announce message to a daemon process in the system. The system de-fined events include clock events, file system events, machine events, process events, user events, and terminal events. The daemon process maintains ta-bles of event definitions and event-action specifications which specify a com-bination of events and an action. The daemon process further keeps track of the occurrence of system- and user-defined events and performs the action specified in an event-action specification when the events specified therein have occurred. The actions may include commands which affect the event definition and event-action specification tables. Events are defined in terms of objects and attributes. An event has occurred when an attribute of an instance of an object is set to a value which is specified for the attribute. The attributes may be predefined or may be user-defined. Values are set in predefined attributes by system defined events and in user-defined attributes by the announce message.

Automobile shock absorbers controlling appts.

The appts. includes a shock absorber having a cylinder divided by piston into two working chambers. A sensor is used to generate an electrical signal in response to the pressure differential between the damping fluid in the two working chambers. A second sensor is used for determining the movement of the body of the automobile. An electronic control module generates an electrical control signal in response to the outputs of the first and second sensors. The signal is used to control a solenoid regulating the flow of damping fluid between the working chambers. The solenoid comprises plunger part (248) which has a region (254) able to connect or disconnect flow passages (262, 264). When disconnected, firm damping is generated during compression and rebound.

Shielded interface connector

SHIELDED INTERFACE CONNECTOR A connector is provided, of the type that includes a largely insulative insert device (14) that fits closely into a metal shell (24), and wherein the metal shell fits into a diecast housing (32) that can be tightly clamped in place, wherein the insert device and shell are separately held to the housing. The housing has a vertical hole (34) for receiving the insert, and has horizontally-opening slots (46, 48) at opposite ends of the hole. The shell has a casing portion with a vertical hole (26) that closely receives the insert, and has a pair of largely horizontal flange portions (42, 44) that fit into the slots in the housing, until the holes in the housing and shell are aligned so the insert device can be received in both of them. The flange portions are bent in a largely wave-like manner, to provide good electrical connection with the walls of the slots in the housing.

Systems and methods for controlling third-party access of a protected data resource

A method for controlling third-party access of a protected resource is disclosed. The method includes: receiving, from a client device associated with a user account at a protected resource, an indication of access permissions for a first application to access the user account, the access permissions defining at least one permission level and one or more permitted user account operations that are associated with the at least one permission level; receiving a request for the first application to access the user account for performing a first access operation; determining that the first access operation is not among the one or more permitted user account operations; in response to determining that the first access operation is not among the one or more permitted user account operations: providing, to the client device, a request for a one-time authorization for the first application to access the user account for performing the first access operation; receiving, from the client device, an indication of the requested one-time authorization; and granting, to the first application access to the user account.

An ex vivo human multiple myeloma cancer niche and its use as a model for personalized treatment of multiple myeloma

The described invention provides an ex vivo dynamic multiple myeloma (MM) cancer niche contained in a microfluidic device. The dynamic MM cancer niche includes (a) a three- dimensional tissue construct containing a dynamic ex vivo bone marrow (BM) niche, which contains a mineralized bone-like tissue containing viable osteoblasts self-organized into cohesive multiple cell layers and an extracellular matrix secreted by the viable adherent osteoblasts; and a microenvironment dynamically perfused by nutrients and dissolved gas molecules; and (b )human myeloma cells seeded from a biospecimen composition comprising mononuclear cells and the multiple myeloma cells. The human myeloma cells are in contact with osteoblasts of the BM niche, and the viability of the human myeloma cells is maintained by the MM cancer niche.

Low voltage electrical distribution system

Abstract A distribution bus 12 comprises a conductor sheet 16 and another electrode 18 separated by an insulating sheet 20 of foamed plastic or foamed glass, or by air. A jack plug 14 can be plugged in anywhere on the bus 12 by poking a contact pin 44 through a hole 64 in the conductor sheet 16 to contact the other electrode 18, and poking a contact sleeve 46 through the same hole 64 to contact the conductor sheet 16. The jack plug 14 is clipped to the bus 12 by clips 62 which are pushed through other holes 64 in conductor sheet 16 and are cammed by a rotatable wheel 28 into operative position.

System and method for pre-encryption of transmitted content

A system and a method for the creation and transmission of 'pre-encrypted' digital content, which is encrypted before being placed on a distributed media transmission server. Preferably a plurality of such servers are used, for example in order to be able to place such a media transmission server in physical proximity to the end user client, whether in terms of geographical proximity or proximity through the network. Use of a plurality of transmission servers also optionally enables the media content to be transmitted flexibly, according to the request of the end user through the end user client.

An air removal system

TICKET, SHORT E.L.

INCORRECT CONTENTS

An ex vivo human multiple myeloma cancer niche and its use as a model for multiple myeloma

The described invention provides an ex vivo dynamic multiple myeloma (MM) cancer niche contained in a microfluidic device. The dynamic MM cancer niche includes (a) a three- dimensional tissue construct containing a dynamic ex vivo bone marrow (BM) niche, which contains a mineralized bone-like tissue containing viable osteoblasts self-organized into cohesive multiple cell layers and an extracellular matrix secreted by the viable adherent osteoblasts; and a microenvironment dynamically perfused by nutrients and dissolved gas molecules; and (b )human myeloma cells seeded from a biospecimen composition comprising mononuclear cells and the multiple myeloma cells. The human myeloma cells are in contact with osteoblasts of the BM niche, and the viability of the human myeloma cells is maintained by the MM cancer niche.

Touchless payments at point-of-sale terminals

In some implementations, a method of providing contactless payments at a point of sale terminal includes: causing a point-of-sale terminal processing a transaction to display a machine-readable code, the machine-readable code encoding a web address; receiving a request from a device that scanned the machine-readable code, the request received at the web address; in response to receiving the request, causing the device that scanned the machine-readable code to output an interface that includes a prompt for input required to complete the transaction; receiving a response to the prompt; and sending an indication of the response to the prompt to the point-of-sale terminal to allow for completion of the transaction based on the response at the point-of-sale terminal through use of a physical token at the point-of-sale terminal.

Comb hanger straightening method and device

Table

Vapour barrier

A water meter has a glass window (30) having an aperture (32) through which extends one or more screw threaded terminals (20) enabling electrical connection to be made to an internal electronic encoder. A resilient grommet (34) is positioned in the aperture (32) and is held in compression between inner and outer sealing plates (36, 38). These are drawn together by the terminals which carry nuts.

Wind turbine rotor blade with porous window and controllable cover member

A wind turbine blade includes a porous window defined in the suction side of the blade. The porous window is permeable to airflow from within an internal cavity of the blade through the suction side. A deployable cover member is configured with the porous window and is variably positionable from a fully closed position wherein airflow through the porous window is blocked, to a fully open position wherein airflow is established through an entirety of the porous window. An actuating mechanism is disposed within the internal cavity of the blade and is configured with the cover member to move the cover member between the fully closed and fully open positions in response to a control signal.

Organic compounds

This invention relates to sphingoglycolipid analogues, compositions comprising these compounds, processes for preparing the compounds, and methods of treating or preventing diseases or conditions using the compounds, such as diseases or conditions relating to infection, atopic disorders, autoimmune disease, diabetes or cancer.

A chemical process

A novel process for preparing cimetidine polymorph "B" comprises precipitating cimetidine from an aqueous-alcoholic solution of an acid addition salt. The precipitation is conducted at a temperature of above 15 DEG C.

Process for the polymerization of ethylene

Method and apparatus for a remote tire pressure monitoring system

A tire characteristic monitoring method allows automatic programming of tire position information in a remote tire pressure monitoring system (10). The method includes, from a remotely located exciter (16) using a primary coil (18) to transmit a relatively low frequency signal to a secondary coil (L1) of a tire monitor (12) associated with a tire of a vehicle. The method further includes the step of, at the tire monitor, in response to the relatively low frequency signal, transmitting a relatively high transmitting signal to convey data. The data are received at the exciter and subsequently loaded into a receiving unit (14) of the vehicle.

Behavioral recognition system

Embodiments of the present invention provide a method and a system for analyzing and learning behavior based on an acquired stream of video frames. Objects depicted in the stream are determined based on an analysis of the video frames. Each object may have a corresponding search model used to track an object's motion frame-to-frame. Classes of the objects are determined and semantic representations of the objects are generated. The semantic representations are used to determine objects' behaviors and to learn about behaviors occurring in an environment depicted by the acquired video streams. This way, the system learns rapidly and in real-time normal and abnormal behaviors for any environment by analyzing movements or activities or absence of such in the environment and identifies and predicts abnormal and suspicious behavior based on what has been learned.

Phosphatidylinositol mannosides and analogues thereof

Disclosed is a phosphatidylinositol mannoside (PIM) analogue of the formula (I): where X1 and X2 are H, or taken together form a 6-membered carbocyclic ring which is optionally substituted with one or more groups selected from OH, halogen, alkyloxy, acyloxy and NH2; Y1 and Y2 are independently H, OH, or a saccharide having 1 to 5 glycosyl or glycosyloxy units and the other substituents are defined herein. Also disclosed is a pharmaceutical composition containing a compound as defined above, and one or more pharmaceutically acceptable carriers, excipients, or diluents. The use of a compound as defined above in the manufacture of a medicament for treating or preventing infection, an atopic disorder, or cancer is further disclosed.

Apparatus and method using an electric field for creating uniform nanofiber patterns on nonconductive materials to enhance filtration and for embedment of fibers into materials for other applications

A filtration device including a base filtration material having openings for fluid flow there through and a filtration medium. The filtration medium includes a plurality of patterned nanofibers formed on the base filtration material. The filtration medium has a figure of merit greater than 30 kPa -1 , where the figure of merit is given by -Log (Pt)/ΔP, where Pt is the fractional penetration of a specific aerosol particle diameter and ΔΡ is a pressure drop across the filtration medium corresponding to a face velocity of 5.3 cm/s and particle size of 0.3 microns.

System for presenting and managing enterprise architectures

A system providing views of a technical architecture of an enterprise that take into account the content type interest, level of detail and time frame of desired information. A user, with a browser interface, selects a portal specifying the type of content to be viewed. A profile of the user indicates the level of detail and time frame of information to be obtained. The interface provides the user's selection of desired information within the portal in the form of a page request that is converted into queries of a database that seek content satisfying the type, level of detail and time frame attributes of the request. The content is formed into a web page and provided to the interface by the web server. Content is separated into atomic units allowing the information to be rearranged responsive to each user's needs.

Systems and method for evaluating security of third-party applications

A method for evaluating security of third-party application is disclosed. The method includes: receiving, from a first application, a request to obtain first account data for a user account associated with a protected data resource; generating fake data for at least a portion of the requested first account data; providing, to the first application, a first data set in response to the request, the first data set including at least the generated fake data; monitoring use of the first data set by the first application; detecting a trigger condition indicating misuse of account data based on monitoring use of the first data set by the first application; in response to detecting the trigger condition, generating a notification identifying the misuse of account data; and transmitting the notification to a computing device associated with an application user.

Impression roller, and a method for manufacturing such

An impression roller (10) for use with a lamination system (100) configured to produce a packaging material (20) is provided. The impression roller comprises a rigid core (12) exhibiting a circular-cylindrical jacket surface, and a layer (14) of elastic material arranged radially outside said rigid core (12). The impression roller (10) further comprises a sleeve (16) of fluoropolymer material arranged radially outside the layer (14) of elastic material and extending along the major part of the longitudinal extension of the layer (14) of elastic material.

4-AMINO-BENZO (B) BICYCLO ANGLE CLAMP ON 3,3,1 ANGLE CLAMP ON -NON-DERIVATIVES AND METHOD FOR THEIR PRODUCTION AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS

Automated multi-level marketing system

A method for automated multi-level marketing of an electronic item. The method includes providing a secured electronic item originating from a distributor, and a first user packaging a copy of the secured electronic item with secured payment details for the first user to receive a payment, thereby producing a packaged secured electronic item. Related apparatus and methods are also described.

Vehicle cab windows

A vehicle cab (10) with a window aperture (11) closed by a pivotable glazing panel (12). The window aperture is of vertically tapering form such that the width 'W' of the lower regions of the aperture is less than higher regions of the aperture and the glazing panel (12) is of a similar vertically tapering form. A glazing panel mounting structure (13) allows the glazing panel to be moved from a generally upright closed position to a generally horizontal open position (12′) by raising the panel in a vertical sense so that the lower narrower portion of the panel is in alignment with a wider higher portion of the aperture and then pivoting the lower narrower portion of the glazing panel about a first generally horizontal axis (21) through the wider higher portion of the aperture to its generally horizontal open position. The locus (60) of the glazing panel as it moves between its closed and open positions may be controlled to a predetermined pattern by a linkage (42, 49, 50, 51, 52) which inter-connects the movements of the mounting structure and glazing panel relative to the cab.

Table

ELECTRICAL CONNECTOR FOR FLAT TRANSFER ON PRINTED CIRCUIT BOARD.

Alumina forming bimetallic tube for refinery process furnaces and method of making and using

Provided is a bimetallic tube for transport of hydrocarbon feedstocks in refinery process furnaces, and more particularly in furnace radiant coils, including: i) an outer tube layer being formed from stainless steels including chromium in the range of 15.0 to 26.0 wt.% based on the total weight of the stainless steel; ii) an inner tube layer being formed from an alumina forming bulk alloy including 5.0 to 10.0 wt.% of AL 20.0 wt.% to 25.0 wt.% Cr, less than 0.4 wt.% Si, and at least 35.0 wt.% Fe with the balance being Ni, wherein the inner tube layer is formed plasma powder welding the alumina forming bulk alloy on the inner surface of the outer tube layer; and iii) an oxide layer formed on the surface of the inner tube layer, wherein the oxide layer is substantially comprised of alumina, chromia, silica, mullite, spinels, or mixtures thereof. Also provided are methods of making and using the bimetallic tube.

2ª‰-amino-3ª‡-hydroxy-5ª‡-steroids and the preparation thereof

Novel steroids of the formula <FORM:1039441/C2/1> wherein Y is H2, H(b OH), H(a OH), H(a O acyl) or O; R1 is C1- 6 alkyl or hydroxy-ethyl; R2 is hydrogen, C1- 6 alkyl or hydroxy-ethyl; or NR1R2 is a saturated heterocyclic amino radical; and X is <FORM:1039441/C2/2> in which R3 is hydrogen or C1- 6 alkyl; and Z is H(b OH), H(b O acyl), H(a COCH3), H(b COCH3), H(b CHOHCH3), H(b CHO acyl CH3) or OH(b COCH3), are prepared by reacting the corresponding 2a ,3a -epoxides with the amine NHR1R2. If the product is to be a 20-keto compound, the starting material may be a 20-ketal which is hydrolysed after the amination reaction. 17-Keto products may be reduced to the 17-ols, or a 17- or 20-keto group in a starting material may be reduced before the amination. Free hydroxy groups in the products may be oxidized or esterified, and some of the 3-esters are also novel. The products may also be converted into novel acid-addition salts and quaternary ammonium derivatives with alkyl halides. Examples are given. 2a ,3a -Epoxides used as starting materials are prepared from the corresponding D 2-compounds (prepared, in turn, by heating 3-tosyloxy steroids, prepared from the 3-ols and tosyl chloride, with a base) and per-acids. 5a -pregn-2-en-20b -ol is prepared by reducing 2a -bromo-5a -pregnane-3,20-dione with sodium borohydride and then zinc; or by reduction of 5a -pregn-2-en-20-one. The last-named is also converted to a 20-ketal before epoxidation. 3a ,4a -Epoxy-5a -pregnan-20b -ol is a by-product in the reaction of 2a ,3a -epoxy-5a -pregnan-20b -ol with morpholine. 16a -Ethyl-5a -pregnan-3b -ol-20-one is prepared by hydrogenation of the D 5-compound. 5a -Pregn-2-en-11a -ol-20-one is prepared by hydrolysis of the 11-acetate, and on oxidation gives 5a -pregn-2-ene-11,20-dione, which on ketalization gives the 20-ketal. 16a -Methyl-5a -pregn-2-ene-11,20-dione is prepared by tosylating 16a - methyl - 3b ,11a - dihydroxy - 5a - pregnan-20-one 11-acetate (prepared by ...

System and method for establishing secure communication between applications

A computer-implemented method is disclosed. The method includes: receiving, via a first application on the computing device, a request to connect a first data record associated with the first application with a second data record associated with a second application on the computing device; and establishing a secure communication channel between the first application and the second application, the secure communication channel enabling transmission of data between the first application and the second application, wherein establishing the secure communication channel comprises: sending, to the second application, identifying information for the first data record and a first device token associated with the first application; receiving, from the second application, a second device token associated with the second application; and causing the second device token to be stored, in the memory, in association with the first application.

DEVICE FOR USING A VIRTUAL CHIP CARD

2-BETA MORPHOLINO ANDROSTAN DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF.

Conjugate compounds

The invention relates to sphingoglycolipid analogues and peptide derivatives thereof, which are useful in treating or preventing diseases or such as those relating to infection, atopic disorders, autoimmune diseases or cancer.

Improvements relating to tickets, cards or the like

The invention resides in that a lottery or other ticket or card comprises two sheet sections which are relatively hingeable, and hinging the sections causes erection of pop-up panels defined in one sheet section by means of lines of cutting and creasing. The pop-up panels not only give the ticket the novelty of surprise, but also serve as a means of security as when the ticket has been unfolded once, it retains a certain amount of permanent creasing which cannot be concealed by reclosing the ticket.